Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant

This study has been completed.
Sponsor:
Information provided by:
Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00179049
First received: September 13, 2005
Last updated: December 12, 2008
Last verified: December 2008
History of Changes
  Purpose
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.

Condition
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Vanderbilt University:
Estimated Enrollment: 100
Study Start Date: April 2003
Study Completion Date: April 2008
Detailed Description:
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease (GVHD) by determining the qualitative and quantitative changes in T regulatory cells throughout the transplant process. Their understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.
  Eligibility
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions
Criteria

Inclusion Criteria:

  • Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions

Exclusion Criteria:

  • Patients < 18 or > 70 years old undergoing either autologous transplant or allogeneic transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00179049

Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-5505
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Adetola A Kassim, M.D. Vanderbilt University
  More Information

Responsible Party: Adetola A. Kassim, MD, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00179049     History of Changes
Other Study ID Numbers: BMT 030261 
Study First Received: September 13, 2005
Last Updated: December 12, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
T-Lymphocyte Subsets

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases

ClinicalTrials.gov processed this record on September 29, 2016